Gilead and Kite nab another approval for Tecartus, as leading CAR-T portfolio continues to grow
Gilead and Kite took another step Friday toward expanding their franchise of CAR-T drugs, nabbing a new approval for Tecartus.
The FDA OK’ed the therapy for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, Gilead announced Friday. It’s the drug’s second indication after Gilead initially launched the CAR-T in 2020 for adults with relapsed or refractory mantle cell lymphoma.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.